Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | President, Head of R&D | February 10, 2025 | February 12, 2025 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | December 10, 2024 | December 12, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Syndax Pharmaceuticals Inc
Report date February 10, 2025 · Filed February 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,095 |
Reported balance
After 2025-02-10 transaction · row 1
1 source rowRow 1 · 2025-02-10 · Sale · Disposed 4,618 · Balance 85,095 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units.
Zymeworks Inc.
Report date December 10, 2024 · Filed December 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.06 · Expires 2034-12-09 | Direct | 31,000 |
Reported balance
After 2024-12-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-10 · Grant · Acquired 31,000 · Balance 31,000 F1: Stock options vest on date of next annual general meeting following grant date of December 10, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of December 10, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 20:04 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 28,000 | $4.08 Strike: $4.08 | $114,240.00 |
DisclosureSEC source: 0001972849-26-000004 · primarydocument.xml · derivative · entry 1 Gallagher Neil · CIK 0001972849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:04 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 50,000 | $4.16 Strike: $4.16 | $208,000.00 |
DisclosureSEC source: 0001562180-25-003475 · primarydocument.xml · derivative · entry 1 Gallagher Neil · CIK 0001972849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-04-30 F1 · derivative.exercise_date: The options will vest as to one-third of the underlying shares of common stock on each of the first three anniversaries of the date of grant, subject to the recipient's continuing service on the board of directors. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 22:13 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | SaleCommon Stock | 4,618 | $15.50 | $71,597.47 |
DisclosureSEC source: 0000950170-25-018993 · ownership.xml · nonDerivative · entry 1 Gallagher Neil · CIK 0001972849 · President, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,095 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:45 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 110,500 | $14.65 Strike: $14.65 | $1,618,825.00 |
DisclosureSEC source: 0000950170-25-016391 · ownership.xml · derivative · entry 3 Gallagher Neil · CIK 0001972849 · President, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,500 Underlying: Common Stock · 110,500 shares Expires 2035-02-05 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:45 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 23,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016391 · ownership.xml · nonDerivative · entry 2 Gallagher Neil · CIK 0001972849 · President, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,713 F2 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:45 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 18,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-016391 · ownership.xml · nonDerivative · entry 1 Gallagher Neil · CIK 0001972849 · President, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,313 F1 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 22:49 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0000950170-24-135919 · ownership.xml · derivative · entry 1 Gallagher Neil · CIK 0001972849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 10, 2024. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 01:54 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 74,000 | $0.00 Strike: $9.23 | $0.00 |
DisclosureSEC source: 0000950170-24-040632 · ownership.xml · derivative · entry 1 Gallagher Neil · CIK 0001972849 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,000 Underlying: Common Stock · 74,000 shares Expires 2034-04-01 F1 · derivative.exercise_date: Stock options vest in 36 equal monthly installments starting one month after grant date of April 2, 2024. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 69,375 | $22.28 Strike: $22.28 | $1,545,675.00 |
DisclosureSEC source: 0001562180-24-001221 · primarydocument.xml · derivative · entry 3 Gallagher Neil · CIK 0001972849 · President, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,375 Underlying: Common Stock · 69,375 shares Expires 2034-02-07 F3 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 13,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001221 · primarydocument.xml · nonDerivative · entry 2 Gallagher Neil · CIK 0001972849 · President, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,813 F2 · shares: Award of RSUs, representing the right to receive one share of Common Stock for each RSU. The number of shares of Common Stock acquired upon vesting of the RSUs is contingent upon the achievement of pre-established performance metrics, as approved by the Company's Compensation Committee, subject to the Reporting Person's continued service as an employee, consultant, director or officer of the Company. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 21:05 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantCommon Stock | 34,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-001221 · primarydocument.xml · nonDerivative · entry 1 Gallagher Neil · CIK 0001972849 · President, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,688 F1 · shares: Award of restricted stock units ("RSUs"), representing the right to receive one share of Common Stock for each RSU. One third (1/3rd) of the shares of Common Stock subject to such RSU shall vest annually on the anniversary of the Vesting Commencement Date, during the Reporting Person's continued service as an employee, consultant, director or officer of the Company over the three (3) years following the date of grant, until all of the shares subject to such RSU are fully vested. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:02 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 250,000 | $19.35 Strike: $19.35 | $4,837,500.00 |
DisclosureSEC source: 0001562180-23-003520 · primarydocument.xml · derivative · entry 1 Gallagher Neil · CIK 0001972849 · President, Head of R&D 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-04-10 F1 · derivative.exercise_date: Twenty five percent (25%) of the total number of shares underlying the option shall vest on April 10, 2024, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.